Anika Therapeutics (NASDAQ:ANIK) Issues FY 2021 Earnings Guidance

Anika Therapeutics (NASDAQ:ANIK) updated its FY 2021 earnings guidance on Tuesday. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $143.50 million-147.42 million, compared to the consensus revenue estimate of $144.15 million.

Separately, Zacks Investment Research raised Anika Therapeutics from a sell rating to a hold rating in a report on Thursday, May 6th.

Anika Therapeutics stock traded down $1.07 during trading on Friday, hitting $43.69. The company’s stock had a trading volume of 2,557 shares, compared to its average volume of 129,933. The stock has a market capitalization of $628.74 million, a PE ratio of -23.68, a price-to-earnings-growth ratio of 24.26 and a beta of 1.21. The stock has a fifty day moving average price of $42.54. Anika Therapeutics has a 1-year low of $31.55 and a 1-year high of $48.37.

Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, May 5th. The biotechnology company reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.19. Anika Therapeutics had a negative return on equity of 0.98% and a negative net margin of 20.83%. The firm had revenue of $34.29 million during the quarter, compared to analyst estimates of $32.39 million. Research analysts expect that Anika Therapeutics will post 0.19 earnings per share for the current fiscal year.

In other news, Director Raymond J. Land sold 2,000 shares of the company’s stock in a transaction dated Wednesday, May 12th. The stock was sold at an average price of $42.60, for a total value of $85,200.00. Following the completion of the sale, the director now owns 7,953 shares of the company’s stock, valued at $338,797.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.09% of the stock is owned by corporate insiders.

About Anika Therapeutics

Anika Therapeutics, Inc, together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses.

See Also: Which market index is the best?

Earnings History and Estimates for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.